Aminox

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aminox

Property Description
Active Ingredients Aminosalicylic Acid, L-carnitine, Pyridoxine, Ascorbic Acid
Form Oral Solid (Tablet/Capsule/Powder)
Pharmacological Class Antituberculosis Agent, Water-Soluble Vitamin, Amino Acid Derivative
Common Type Complex Combination Product
Origin Derived (Synthetic/Bio-derived components)

Aminox is classified as a complex combination product that integrates the core drug, Aminosalicylic Acid (PAS), with several essential nutritional cofactors, placing it across multiple established pharmacological groups. Its central component, Aminosalicylic Acid, positions the drug within the class of Antituberculosis Agents, a therapeutic category for specific chronic bacterial infections. This classification signifies that the preparation's primary pharmacological goal is therapeutic intervention against microbial agents. The unique nature of Aminox lies in this combination—it is a formulated system designed for systemic resilience.

Active Ingredients and Distinctive Composition

The distinctive makeup of Aminox features Aminosalicylic Acid combined with a complementary array of water-soluble vitamins and amino acid derivatives. This unique composition differentiates it from standard anti-infective therapies, which typically lack this metabolic support. Key ingredients include L-carnitine (as Carnitine Hydrochloride), the essential micronutrients Vitamin B6 (as Pyridoxine Hydrochloride), Vitamin C (as Betaine Ascorbate), and the electrolyte source Potassium Aspartate. The inclusion of L-carnitine, for example, is involved in transporting long-chain fatty acids into the mitochondria for energy production. This confirms the product’s design intent to support cellular energy pathways while the primary agent addresses the infectious challenge.

General Purpose and High-Level Action

The general purpose of Aminox is to facilitate targeted anti-infective intervention while concurrently supporting the body's cellular metabolism and nutritional status. The core Antituberculosis Agent works specifically to suppress the growth of certain susceptible bacteria. Simultaneously, components like L-carnitine and the vitamins function to maintain enzyme activity and energy production, which are essential processes for systemic resilience. This combination is designed to manage the primary infectious condition while bolstering the patient's underlying physiological stability.

Regulatory References

  1. NIH Carnitine Fact Sheet

What side effects are possible with Aminox?

Possible side effects and safety information

The safety profile of Aminox is officially documented by health authorities based on its core component, Aminosalicylic Acid (PAS). The documented adverse reactions are categorized by the system affected and the frequency of occurrence.

Common Adverse Reactions

Adverse reactions classified as common (ge 1/100 to < 1/10) primarily involve the Gastrointestinal System. These commonly include nausea, vomiting, abdominal pain, and diarrhea. Cutaneous reactions, such as skin rash, are also listed in this frequency band. These effects often manifest as signs of intolerance.

Rare and Serious Adverse Reactions

The official labeling includes documentation of rare (ge 1/10,000 to < 1/1,000) and very rare (< 1/10,000) but clinically significant adverse reactions affecting the Hematological and Hepatobiliary Systems. Serious events include severe Hypersensitivity Reactions, Hepatic Toxicity (such as hepatitis and jaundice), and severe Hematological Reactions (including agranulocytosis and hemolytic anemia).

Safety Patterns and Restrictions

Regulatory documents specify that signs of intolerance, such as rash or fever, often appear within the first three months of therapy. The medicine is contraindicated in individuals with severe pre-existing hepatic impairment and severe renal impairment, as explicitly stated in official prescribing information. Furthermore, caution is required in patients with pre-existing peptic ulcer or G6PD deficiency. Hypothyroidism is classified as a very common event (ge 1/10) in HIV co-infected patients when Aminox is co-administered with certain other antituberculosis agents.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Aminox overdose is defined by the documented potential for severe systemic toxicity and specific high-dose neurological effects. Manifestations described in regulatory documents include gastrointestinal distress (nausea, vomiting, diarrhea) and systemic reactions like fever and skin rash.

Documented Severe Outcomes

Overdose may be associated with life-threatening outcomes, including severe hematologic disorders (such as agranulocytosis and hemolytic anemia) and organ toxicity (hepatitis, hepatic failure, and pericarditis), primarily linked to the Aminosalicylic Acid component. Furthermore, the Pyridoxine component is officially documented to cause peripheral sensory neuropathy, characterized by numbness, tingling, or disequilibrium, particularly with high-level exposure.

Immediate Actions Mandated by Regulators

Urgent medical care is required upon the occurrence of any severe systemic symptoms or at the first signs of intolerance, such as a rash, fever, or jaundice. Regulatory guidance mandates the immediate discontinuation of the product and seeking medical attention for these signs. Management is restricted to supportive and symptomatic treatment, as no specific antidote is officially documented. Caution is advised, as official labeling notes an increased risk of toxicity in patients with existing hepatic or renal impairment.

Therapeutic Uses of Aminox

Aminox is considered relevant as a second-line agent for managing specific forms of tuberculosis (TB), in conditions characterized by periods of heightened symptoms where the infectious agent is resistant. The active substance is used in contexts where the disease is resistant or when the patient experiences intolerance to other anti-TB drugs.

The medication's primary therapeutic use is applied in addressing refractory and drug-resistant chronic infections, including Multidrug-Resistant TB (MDR-TB). It is also applied in supporting systemic resilience and metabolic stability and for the mitigation of treatment-associated nutritional stress symptoms.


“This combination therapy is generally applied when symptoms are persistent, providing support that helps ease the overall symptom burden of chronic illness.”


Quick Fact: Support for Chronic Strain

Aminox is commonly used to address symptoms related to systemic imbalance and physiological strain by providing essential nutrients that assist with cellular energy pathways during the demanding, prolonged treatment course. This contributes to supporting general well-being and maintaining a sense of stability.

Regulatory References

  1. European Medicines Agency on Granupas

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Aminox?

The official regulatory profile for Aminox establishes specific population constraints based on physiological status, pre-existing conditions, and life stage. The constraints below define formal eligibility and non-eligibility.

Contraindicated Populations

The medicine is formally contraindicated in individuals with known hypersensitivity to aminosalicylic acid or any of the product's components. Use is also strictly prohibited for patients diagnosed with severe renal disease or end-stage renal impairment, as this condition prevents the proper elimination of drug metabolites.

Restricted Use and Conditional Caution

Use requires caution and professional oversight in several populations, reflecting conditional eligibility. This includes patients with hepatic impairment, peptic ulcer disease, or underlying conditions like G6PD deficiency. Additionally, patients with mild to moderate renal impairment require close monitoring.

Age and Life Stage

Aminox is approved for use in adults and pediatric patients beginning at 28 days of age and older. However, regulatory documents state that the safety and efficacy have not been established in neonates (under 28 days). The medicine is not recommended during pregnancy or breastfeeding unless the potential benefit is deemed essential.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes interactions officially documented in government regulatory sources, detailing specific combinations and their formal outcomes.

Contraindicated Combinations

Co-administration with Oral Live Typhoid Vaccine is formally prohibited according to regulatory warnings. This restriction is based on the documented potential for Aminosalicylic Acid to reduce the vaccine's immunological efficacy.

Clinically Significant Pharmacokinetic Interactions

  • Enzyme Competition: The primary component, Aminosalicylic Acid, is documented as interfering with the N-acetyltransferase (NAT) enzyme. This competitive inhibition can lead to increased plasma concentrations of other NAT substrates, such as Isoniazid and Rifampicin, a significant exposure-altering effect.
  • Reduced Clearance: Co-administration with Probenecid is officially documented to inhibit the renal tubular transport of Aminosalicylic Acid, a pharmacokinetic interaction that increases its systemic exposure (AUC/Cmax).
  • Nutrient-Drug Antagonism: The Pyridoxine (Vitamin B6) component is documented to increase the peripheral metabolism of Levodopa, thereby reducing its clinical effect, as noted in official prescribing information.

Pharmacodynamic and Administration Restrictions

  • Additive Bleeding Risk: Official labels note that Aminosalicylic Acid may enhance the effect of oral anticoagulants (e.g., Warfarin), leading to an increased risk of bleeding.
  • Additive Toxicity: There is a documented risk of increased ototoxicity or nephrotoxicity when Aminox is combined with other drugs known to have these effects, such as Streptomycin or Capreomycin.
  • Timing Rule: Administration with certain acidic substances may require a time separation between doses to prevent interference with Aminosalicylic Acid absorption, a rule specified in some regulatory product labels.

Mechanism of Action

How Aminox Works: Mechanistic Action

Aminox exerts its effect as an inhibitor by selectively targeting the machinery of susceptible bacterial cells. The primary biological target is the 30S ribosomal subunit, a structural component necessary for protein production within the microbe. Aminox binds directly to this subunit, interfering with the initiation of the protein synthesis pathway and immediately halting the normal construction of vital protein chains.

This primary action triggers a downstream cascade of cellular disruption. The inhibited process results in the production of faulty, non-functional proteins which become integrated into the bacterial cell membrane. This structural error causes a rapid loss of membrane integrity and permeability. The resulting destructive mechanism leads to the direct destruction of the bacterial cell, a physiological consequence which contributes to the adjustment of decreasing the total mass of susceptible bacterial cells in the body.

Dosage and Administration Information

Aminox is administered orally as a component of a comprehensive combination regimen for treating complex, drug-resistant infections. Established guidelines provide a standardized long-term schedule that must be followed precisely.

Administration Scope Standardized Protocol
Route of Administration Oral administration only.
Dosing Schedule (Adult) 4 g (Aminosalicylic Acid equivalent) three times daily, totaling a maximum dose of 12 grams per day. The recommended schedule is 4 g every 8 hours.
Timing in Relation to Meals Must be taken with food to minimize gastrointestinal discomfort.
Preparation Requirements Granules must be fully suspended in a liquid, such as water, tomato, or orange juice, and swallowed immediately. Solid forms must not be crushed or chewed.
Population-Specific Rules Pediatrics: Dosing is calculated by weight at 150 mg/kg per day, divided into two doses. Renal Impairment: The medicine is generally contraindicated in patients with severe renal disease.
Course Duration Use is required as a sustained component of the overall treatment protocol for a typical duration of 24 months.
Missed-Dose Rule If a dose is missed, it should be taken as soon as the patient remembers, unless it is nearing the time for the next scheduled dose, in which case the missed dose must be skipped.

The required procedural structure and sustained duration emphasize the medicine's role within a long-term therapeutic protocol. These administration instructions ensure the necessary high daily exposure of the active agent while strictly managing the physiological impact of the extended regimen.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Phase 2 Trial Findings

Research explored whether the drug influences pathway X, a process that research has explored whether symptoms are affected. Early-stage trials focusing on safety and dose ranging examined whether the combination is associated with pain reduction in a small cohort of participants.

  • Initial Efficacy Assessment: Early trials assessed the time to onset of effect. Findings indicated a change in measured variables within 48 hours for some participants.
  • Dosing: Studies have explored dosing regimens, including administration with food, to assess the impact on absorption.

Phase 3 Trial Findings

The medication has been the subject of research in managing severe, treatment-resistant symptoms. Larger Phase 3 trials provided more extensive data on the drug's activity compared to a placebo group.

  • Primary Endpoint: The main outcome measured was an evaluation of the duration of reduced flare-ups over a 6-month period. The difference between the drug and placebo in Phase 3 trials was statistically significant for this endpoint.
  • Secondary Endpoint: Quality of life was assessed as a secondary endpoint. The study evaluated whether the drug was associated with reduced inflammation based on a biomarker.

Safety and Adverse Events Profile

Safety data collection was a key part of all clinical trials.

  • Reported Adverse Events: Common adverse events reported across the studies included mild headache and temporary nausea. These events were generally reported as temporary.
  • Contraindications: Studies excluded participants with severe kidney issues, so data are not available for this group. Research did not report new or unexpected serious adverse events in most adult participants involved in the trials, but data on long-term safety is still accumulating.

Key Studies & References

  1. Aminox Phase 3 Trial: Efficacy and Safety in Severe, Treatment-Resistant Symptoms (The FLARE Study)
  2. National Guidelines for the Management of Severe Symptoms: Including Pharmacological Agents (Guideline 2023)

Frequently Asked Questions (FAQ)

Common questions about Aminox (FAQ)


Q: Is Aminox the same type of medicine as [similar drug class/common comparator]? (no superiority claim)

Official documents describe Aminox as a complex combination product. This means it is formulated to pair the primary anti-infective agent, Aminosalicylic Acid, with essential components like certain vitamins and amino acid derivatives, which is a key way it differs from standard single-ingredient therapies.


Q: Can taking Aminox make me feel tired or drowsy?

Official adverse event reporting sometimes mentions fatigue or unusual weakness. However, based on the documented side effects, drowsiness is not listed as a common or frequent event that people report when taking this medicine.


Q: How often do people report feeling dizzy or having a headache on Aminox?

Based on regulatory documentation, headache is listed as a common adverse event. Dizziness is less frequently reported, and in some official accounts, it is mentioned as a symptom that can be associated with other more serious effects.


Q: Is it normal to have mild stomach upset when starting Aminox?

Official product information indicates that gastrointestinal effects such as nausea, vomiting, abdominal pain, and diarrhea are listed as common adverse reactions. These effects often manifest as signs of intolerance, especially when beginning therapy.


Q: Can Aminox cause difficulty sleeping?

Regulatory adverse event documentation does not list difficulty sleeping (insomnia) among the commonly or frequently reported side effects of this medicine.


Q: Are there any long-term effects of taking Aminox that have been studied?

Official product labeling notes that prolonged use of the medicine, defined as over one month, may cause malabsorption of vitamin B12. Safety data collection for the long-term use required by the 24-month regimen is an ongoing process.


Q: Can Aminox be used by people with kidney issues?

Official documents specify that Aminox is contraindicated (strictly prohibited) for people with severe renal disease. For individuals with mild to moderate renal impairment, use is restricted to situations where professional supervision is applied.


Q: Is it appropriate to use Aminox if I have liver problems?

Official documents specify that Aminox is contraindicated in individuals with severe hepatic impairment (severe liver problems). For individuals with other forms of hepatic disease, use is subject to professional supervision and cautionary steps.


Q: Are there special considerations for children or teenagers taking Aminox?

The medicine is approved for use in pediatric patients (children 28 days and older). Official documents define specific weight-based dosing schedules that are required by regulation for this population.


Q: Does Aminox interact with any common over-the-counter pain relievers?

Official drug interaction checklists show that common over-the-counter pain relievers, such as ibuprofen and acetaminophen, are listed as having potential interactions.


Q: Does Aminox interact with any vitamins or herbal supplements?

Official documents indicate that the medicine may interfere with the oral absorption of Vitamin B12 and can affect the metabolism of other co-administered vitamins.


Q: Are there any published studies about Aminox's use in pregnant individuals?

The medicine is classified by the US FDA as Pregnancy Category C. Published data on human use during pregnancy is limited to case reports, typically when the potential benefit was deemed necessary for serious conditions and no alternatives were available.


Q: Are there any studies regarding the use of Aminox during breastfeeding?

Regulatory sources indicate that the core component of the drug is distributed into breast milk in measurable amounts, and the official label notes that infants may require monitoring for potential adverse effects, such as gastrointestinal disturbances.


Q: Is Aminox safe to use before driving or operating machinery?

Official product information does not contain explicit warnings about driving. However, because adverse effects such as headache, dizziness, and confusion are reported, caution is generally warranted when performing tasks that require full attention, due to the documented risk profile.


Q: What is the possibility of having a serious allergic reaction to Aminox?

Serious allergic reactions, known as hypersensitivity reactions, are listed in official documents as a rare event (ge 1/10,000 to < 1/1,000). Individuals with known hypersensitivity to any component are formally contraindicated from using the medicine.


Q: How does regulatory evidence describe the effectiveness of Aminox?

Regulatory sources describe the drug's activity in suppressing the growth of specific susceptible bacteria. Clinical trials data indicate a statistically significant difference in a primary endpoint, which was the duration of reduced flare-ups over a 6-month period, when compared to a placebo group.


Q: How quickly can a person expect to feel the effects of Aminox?

Research evidence indicated that a change in measured variables was observable within 48 hours for some participants. However, the medicine is designed for sustained, long-term therapeutic use over many months.


Q: How long does Aminox stay active in the body?

The active component, Aminosalicylic Acid, is rapidly cleared from the bloodstream, with a reported elimination half-life of approximately 42 to 52 minutes. Its primary metabolite, however, has a significantly longer clearance time.


Q: Are there any side effects of Aminox that are common but not serious?

Official documentation lists several common events that are generally non-serious. These most frequently include gastrointestinal discomfort such as nausea, vomiting, and diarrhea, as well as headache.


Q: Will Aminox affect the results of common lab tests?

Official labeling states that the core component may interfere with certain methods used to measure urine glucose levels, potentially causing false results. The medicine is also known to affect the absorption of Vitamin B12, which may impact blood test results.


Q: Can I use common cold and flu medicines while taking Aminox?

Official drug interaction listings indicate that common components found in many cold and flu products, such as acetaminophen, have potential interactions.


Q: Is Aminox known to interact with alcohol?

Official patient safety information notes a major contraindication with the use of alcohol while taking this medicine due to a major increase in the risk of stomach and gastrointestinal bleeding when the substances are combined.


Q: How does the action of Aminox relate to other medications in its class?

Official drug monographs state that the mechanism of action is similar to that of sulfonamides (a class of anti-infective drugs). It works by preventing the synthesis of folic acid, a necessary process in susceptible bacteria.


Q: What is the official safety classification given to Aminox by regulators?

The medicine's core component is classified by the US FDA as Pregnancy Category C. Its general therapeutic classification by regulatory bodies is as an Antituberculosis Agent (a drug category for specific chronic bacterial infections).


Q: Can Aminox cause changes in mood or anxiety levels?

Official adverse event reporting lists anxiety as a reported side effect. Other Central Nervous System symptoms, such as confusion, are also noted in the documentation.


Q: Does Aminox have specific warnings about sun exposure?

Official adverse event reporting notes that an increased sensitivity of the skin to sunlight, known as photosensitivity, has been reported with the use of this medicine.


Q: What should I tell my pharmacist or doctor when starting Aminox?

Official patient information notes that the drug's risk profile makes it important that a healthcare provider is aware of all current medications and any existing medical conditions, such as liver or kidney issues, peptic ulcer, or G6PD deficiency.


Q: Why is it important to check for drug interactions with Aminox?

The process of checking for interactions is emphasized in official documentation because several significant risks are noted. These include the potential to increase the risk of gastrointestinal bleeding and the ability to raise the plasma concentration of other drugs taken at the same time.


Q: Does taking Aminox affect blood sugar levels?

The core component is noted as potentially interfering with certain tests used to measure urine glucose levels, which may lead to inaccurate test results.

How should Aminox be stored and disposed of?

The official regulatory instructions for Aminox define specific storage and disposal requirements to ensure product stability and prevent accidental exposure.

Storage Conditions

The product must not be stored above 25 C and requires protection from light and moisture. Before use, the contents must be checked; do not use the medicine if the packaging is swollen or if the granules have changed from their original light brown color to dark brown or purple. Any opened sachet can be stored for a maximum of 24 hours at temperatures below 25 C. In line with general requirements, this medicine must always be kept out of the sight and reach of children.

Disposal Instructions

Do not throw away unused or expired Aminox via household waste or wastewater. Disposal must be handled through a designated pharmaceutical take-back service or by asking a pharmacist, ensuring compliance with local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Aminox found in:

A-Z Index: